The Clinical Challenge

Minimizing stroke risk remains paramount in TCAR TAVR. Despite advances in embolic protection devices and procedural techniques, the threat of neurological complications persists. The challenge lies in identifying cerebral hypoperfusion in real-time, allowing for immediate corrective action before irreversible damage occurs. Can we reliably detect these subtle changes, and can SSEPs provide a practical and actionable solution?

SSEPs: What the Guidelines Say

Current guidelines offer limited guidance on routine intraoperative neurophysiological monitoring for TAVR. The 2021 ACC/AHA/SCAI Guideline for the Management of Patients With Valvular Heart Disease mentions the importance of neurological assessment but does not specifically recommend SSEP monitoring. This is not a surprise, given the relative paucity of robust data supporting its routine use in this context. The European Society of Cardiology (ESC) guidelines are similarly silent on the issue. Therefore, any adoption of SSEP monitoring must be viewed as adjunctive, not standard of care, until more definitive evidence emerges.

The Case Report Details

The case report describes a patient undergoing TCAR TAVR where SSEP monitoring was employed. A significant decrease in SSEP amplitude was observed during balloon inflation, suggesting compromised cerebral perfusion. The surgical team responded by adjusting the balloon position and flow parameters, which led to a restoration of SSEP amplitude. Post-procedure neurological examination revealed no deficits, suggesting that the SSEP monitoring may have played a crucial role in preventing a stroke. While compelling, this is a single case. It does not establish causality but rather points toward a potential benefit warranting further investigation.

Limitations and Caveats

The most obvious limitation is the single-case nature of the report. We cannot extrapolate these findings to a broader population. Furthermore, SSEPs are susceptible to various confounding factors, including anesthesia depth, body temperature, and pre-existing neurological conditions. The sensitivity and specificity of SSEPs for detecting clinically significant cerebral hypoperfusion during TCAR TAVR remain undefined. It is entirely possible that a decrease in SSEP amplitude could trigger unnecessary interventions, leading to increased procedural time and potential complications. Before widespread adoption, we need prospective studies with clearly defined endpoints and rigorous statistical analysis to determine the true clinical utility of SSEP monitoring in this setting.

Integrating SSEPs into Your TCAR TAVR Program

If your heart team is considering incorporating SSEP monitoring, several practical considerations must be addressed. First, ensure that the anesthesiology team is experienced in SSEP monitoring and interpretation. The baseline SSEP should be established after induction and before any manipulation of the aortic valve. Clear communication protocols must be established between the surgical, anesthesiology, and neurology teams to ensure rapid response to any changes in SSEP amplitude. Finally, the cost of SSEP monitoring should be factored into the overall cost of the TCAR TAVR procedure. This includes the cost of the monitoring equipment, the neurologist's time for interpretation, and any additional resources required to manage potential complications arising from SSEP-guided interventions. A formal protocol, including decision trees based on SSEP changes, is essential to guide intraoperative management.